Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference
Rhea-AI Summary
Evoke Pharma, a specialty pharmaceutical company focusing on gastrointestinal (GI) diseases, announced its participation in the 7th Annual Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Conference from September 12-14, 2024, in National Harbor, Maryland. As a four-year meeting sponsor, Evoke Pharma aims to engage with nurse practitioners and physician assistants who manage patients with GI disorders, including gastroparesis.
The company will host a booth to discuss GIMOTI® (metoclopramide) nasal spray, their treatment for diabetic gastroparesis. CEO Matt D'Onofrio emphasized the importance of connecting with advanced practice providers and showcasing GIMOTI's positive impact on patients. Demittre Sorenson, PA-C, from the Center for Advanced GI, highlighted GIMOTI's effectiveness in treating gastroparesis patients, noting its nasal delivery bypasses the dysfunctional gut.
Positive
- None.
Negative
- None.
News Market Reaction – EVOK
On the day this news was published, EVOK gained 6.20%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that management will participate in the Gastroenterology and Hepatology Advanced Practice Providers Conference taking place from September 12 – 14, 2024 at the Gaylord National Resort Convention Center in National Harbor, Maryland.
“As a meeting sponsor for four consecutive years, we are excited to engage with the advanced practice providers community at the 7th Annual GHAPP conference, a unique event dedicated to nurse practitioners and physician assistants who play a pivotal role in managing patients with gastrointestinal (GI) disorders, including patients with gastroparesis,” said Matt D’Onofrio, CEO of Evoke Pharma. “This year, we look forward to discussing GIMOTI and its positive impact on patients suffering from diabetic gastroparesis.”
Evoke Pharma’s management and commercial team will host a booth at the conference to facilitate discussions with attendees.
“My high level of involvement with GI patients allows me to witness the firsthand challenges of those dealing with gastroparesis. GIMOTI’s nasal delivery offers a promising new option that can improve patient outcomes for those suffering from this disease. My patients benefit from GIMOTI, even if they are having symptoms, as GIMOTI does not rely on the dysfunctional gut to work. I continue to observe this with patients being prescribed GIMOTI in my practice,” Demittre Sorenson PA-C, Center for Advanced GI, Maitland, FL. “The GHAPP conference is a tremendous opportunity for advanced practice providers to learn more about innovative treatments like GIMOTI and to discuss how we can better support patient needs.“
About GHAPP
The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).
The GHAPP conference is the only conference specifically designed by APPs for the purpose of meeting the educational needs of APPs who specialize in the management of patients with GI disorders and chronic liver disease.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.
Visit www.EvokePharma.com for more information.
Follow Evoke Pharma on LinkedIn
Follow Evoke Pharma on Twitter
Safe Harbor Statement
Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should, ”expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2024 net product sales; potential future prescribing trends for GIMOTI based on Evoke’s or EVERSANA’s marketing efforts; Evoke’s commercialization plans, the potential market opportunity for GIMOTI, Evoke’s partnership with ASPN Pharmacies, growth in prescriptions, patients taking GIMOTI and the conversion of prescriptions to fills, and Evoke’s expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke may not be able to achieve its guidance for 2024 including as a result of decreased demand for GIMOTI; Evoke’s and EVERSANA’s ability to successfully drive market demand for GIMOTI; Evoke’s ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; warrant holders may choose not to exercise any of the outstanding warrants; Evoke’s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke’s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor & Media Contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
FAQ
When and where is Evoke Pharma (EVOK) participating in the GHAPP Conference?
What is GIMOTI, the product Evoke Pharma (EVOK) will be discussing at the conference?
How long has Evoke Pharma (EVOK) been sponsoring the GHAPP conference?
What is the main advantage of GIMOTI for gastroparesis patients, according to the press release?
